In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The current rate is a 2.7% gain on diagnosis rates seen before the pandemic and is equivalent to an additional 7,000 early ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Hutchmed has agreed to divest its share of a Chinese joint venture company through a pair of deals that will give it a cash ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

Pfizer's decision could stem from the fairly dismal performance of the only gene therapy for haemophilia A currently on the ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

Looking ahead, the momentum gained in 2024 must be maintained and amplified. By fostering a culture of belonging in the ...